<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303784</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455583</org_study_id>
    <secondary_id>MRC-PATCH</secondary_id>
    <secondary_id>EU-205106</secondary_id>
    <secondary_id>MRC-PR09</secondary_id>
    <secondary_id>ISRCTN70406718</secondary_id>
    <secondary_id>EUDRACT-2005-001030-33</secondary_id>
    <nct_id>NCT00303784</nct_id>
  </id_info>
  <brief_title>Prostate Adenocarcinoma TransCutaneous Hormones</brief_title>
  <acronym>PATCH</acronym>
  <official_title>A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <brief_summary>
    <textblock>
      RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT)
      in the treatment of prostate cancer, usually achieved through the administration of LHRH
      agonists, has raised concerns about long-term toxicities, in particular osteoporosis and
      adverse metabolic changes which may be associated with type II diabetes and increased
      cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral
      oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving
      castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but
      is not used routinely as first-line therapy because of the risk of cardiovascular system
      (CVS) complications. The CVS complications have been attributed to first-pass hepatic
      metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so
      is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing
      testosterone to castrate levels. This hypothesis has been supported by results from the early
      stages of this trial which have provided sufficient indication of the safety and efficacy of
      the patches to warrant further investigation of the treatment in this setting, as recommended
      by the IDMC..

      PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works
      compared with luteinizing hormone-releasing hormone agonist injections in treating patients
      with locally advanced or metastatic prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the progression-free survival and overall survival of patients with locally
           advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs
           luteinizing hormone-releasing hormone analogues.

      Secondary

        -  Compare the cardiovascular system-related morbidity and mortality in patients treated
           with these regimens

        -  Compare the activity of these treatments, in terms of castrate level of hormones,
           failure-free survival, and biochemical failure, in these patients.

        -  Compare other toxicities, including osteoporosis, hot flushes, gynecomastia, and anemia,
           in patients treated with these regimens.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, controlled, multicenter study. Patients are randomized to 1 of
      2 treatment arms at 1(control):1 (patch) ratio.

        -  Arm I (control): Patients receive luteinizing hormone-releasing hormone agonists as per
           local practice in the absence of unacceptable toxicity.

        -  Arm II (patch): Patients receive 4 transcutaneous estrogen patches, changing twice
           weekly for 4 weeks. Patients' testosterone levels are measured at week 4. Patients whose
           testosterone level is &gt; 1.7 nmol/L continue to receive patch as before and have their
           testosterone level measured every 2 weeks. Patients whose testosterone level is &lt; 1.7
           nmol/L at week 4 or any other point receive 3 transcutaneous estrogen patches changed
           twice weekly in the absence of unacceptable toxicity.

      Quality of life is assessed at baseline; at weeks 4, 8, and 12; every 3 months for 24 months.

      After completion of study treatment, patients are followed periodically.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: A total of 2200 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 180 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormone activity by castrate levels of hormones</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other toxicity</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Anemia</condition>
  <condition>Cardiovascular Complications</condition>
  <condition>Hot Flashes</condition>
  <condition>Osteoporosis</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>LHRH agonists</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended &quot;anti-flare&quot; medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oestrogen Patches</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>3.6mg implant, in pre-filled syringe</description>
    <arm_group_label>LHRH agonists</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.</description>
    <arm_group_label>Oestrogen Patches</arm_group_label>
    <other_name>FemSeven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Must meet 1 of the following criteria:

               -  Newly diagnosed patients with any of the following:

                    -  Stage T3 or T4, NX, M0 histologically confirmed prostate adenocarcinoma with
                       prostate-specific antigen (PSA) ≥ 20 ng/mL or Gleason score ≥ 6

                    -  Any T, N+, M0, or any T, any N, M+ histologically confirmed prostate
                       adenocarcinoma

                    -  Multiple sclerotic bone metastases with a PSA ≥ 50 ng/mL without
                       histological confirmation

               -  Patients with histologically confirmed prostate adenocarcinoma previously treated
                  with radical surgery or radiotherapy who are currently in relapse with on of the
                  following:

                    -  PSA ≥ 4 ng/mL and rising with doubling time less than 6 months

                    -  PSA ≥ 20 ng/mL

          -  Must have written informed consent

          -  Intention to treat with long-term androgen-deprivation therapy

          -  Normal testosterone level prior to hormonal treatment

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  No other prior or current malignant disease or cardiovascular system disease that is
             likely to interfere with study treatment or assessment

          -  No cardiovascular disease, including any of the following:

               -  History of cerebral ischemia (e.g., stroke or transient ischemic attack) within
                  the past 2 years

               -  History of deep vein thrombosis or pulmonary embolism confirmed radiologically

               -  History of myocardial infarction (MI) within the past 6 months OR MI more than 6
                  months ago with evidence of q-wave anterior infarct on ECG

                    -  ECHO or MUGA required for patients with history of ischemic heart disease

               -  Left Ventricular Ejection Fraction ≤ 40%

          -  No condition or situation that could preclude protocol treatment or compliance with
             follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 12 months since prior adjuvant or neoadjuvant hormonal therapy for localized
             prostate cancer AND therapy lasted ≤ 12 months in duration

          -  No prior systemic therapy for locally advanced or metastatic prostate cancer

          -  No concurrent participation in another clinical trial of prostate cancer treatment
             that would preclude study therapy or outcome measures

          -  Concurrent prophylactic radiotherapy to prevent gynecomastia allowed
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul D. Abel</last_name>
    <role>Study Chair</role>
    <affiliation>Charing Cross Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton-upon-Trent</city>
        <state>England</state>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1283-566-333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Patterson, MD</last_name>
      <phone>44-122324-5151 ext. 2523 and 2</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-24-7660-2020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Cheshire Hospitals Trust- Leighton Hopsital</name>
      <address>
        <city>Crewe</city>
        <state>England</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. P. Logue, MD</last_name>
      <phone>44-1270-255-141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayday University Hospital</name>
      <address>
        <city>Croydon</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A. Huddart, MD</last_name>
      <phone>44-20-8401-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1332-347-141 ext. 2407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>East Yorkshire</city>
        <state>England</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1482-875-875</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>England</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise J. Sheehan, MD</last_name>
      <phone>44-1392-411-611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grantham and District Hospital</name>
      <address>
        <city>Grantham, Lincolnshire</city>
        <state>England</state>
        <zip>NG31 8DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Daruwala</last_name>
      <phone>44-1476-565-232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Scrase, MD</last_name>
      <phone>44-147-370-4177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidderminster Hospital</name>
      <address>
        <city>Kidderminster Worcestershire</city>
        <state>England</state>
        <zip>DY11 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-190-576-0635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Stewart, MD</last_name>
      <phone>44-207-886-1132</phone>
      <email>s.stewart@imperial.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D. Abel</last_name>
      <phone>44-20-8383-2268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Beesley</last_name>
      <phone>44-1622-729-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1642-850-850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Nottinghamshire</city>
        <state>England</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-162-362-2515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santhanam Sundar</last_name>
      <phone>44-115-969-1169</phone>
      <email>santhanam.sundar@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Nuneaton</city>
        <state>England</state>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-024-7635-1351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexandra Healthcare NHS</name>
      <address>
        <city>Redditch, Worcestershire</city>
        <state>England</state>
        <zip>B98 7UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-015-2750-3030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Salford</city>
        <state>England</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noel Clarke</last_name>
      <phone>44-161-206-5568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough General Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>England</state>
        <zip>YO12 6QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Robertson</last_name>
      <phone>44-1723-368-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stepping Hill Hospital</name>
      <address>
        <city>Stockport</city>
        <state>England</state>
        <zip>SK2 7JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-161-483-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <state>England</state>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvan J. Pope</last_name>
      <phone>44-1895-238-282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walsall Manor Hospital</name>
      <address>
        <city>Walsall</city>
        <state>England</state>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1922-721-172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warwick Hospital</name>
      <address>
        <city>Warwick</city>
        <state>England</state>
        <zip>CV34 5BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1926 495-321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Beard</last_name>
      <phone>44-1903-205-111 ext. 5559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>England</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Parker</last_name>
      <phone>44-1935-475-122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1292-610-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-141-211-2123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Lester, MD</last_name>
      <phone>44-29-2031-6292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Kynaston</last_name>
      <phone>44-2920-745-094</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/patch_pr09/</url>
    <description>Study homepage at the MRC CTU at UCL</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <keyword>anemia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>cardiovascular complications</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

